NeuroSearch starts trials of new epilepsy drug  

2003.02.20
Danish biotech company NeuroSearch has initiated a Phase II clinical study of NS1209 in epilepsy patients

Danish biotech company NeuroSearch has initiated a Phase II clinical study of NS1209 in epilepsy patients. The results are expected August 2003 and will be used for dose selection in later trials with patients suffering from long-lasting seizures. A number of preclinical studies with NS1209 have confirmed that it stops seizures more effectively than known antiepileptic drugs and could help prevent brain damage. The promising results have been presented at epilepsy conferences in Europe and the US.

 

In 2001, worldwide sales of antiepileptic drugs were USD 6.1 billion. Approximately 1% of Western populations suffer from epilepsy and around 20% of all epilepsy patients have long-lasting seizures. Based on the preclinical results, NeuroSearch expects that NS1209 can be used for effective treatment of patients suffering from status epilepticus and other forms of seizures. These patients obtain only limited improvement by treatment with existing epilepsy drugs. The news is reported by the Copenhagen Stock Exchange (CSE).

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×